EF Hutton Reiterates Buy on Atara Biotherapeutics, Maintains $25 Price Target
Portfolio Pulse from richadhand@benzinga.com
EF Hutton analyst Anthony Butler has reiterated a 'Buy' rating on Atara Biotherapeutics (NASDAQ:ATRA) and maintained a $25 price target.
August 09, 2023 | 11:26 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
EF Hutton has reiterated a 'Buy' rating on Atara Biotherapeutics and maintained a $25 price target.
The reiteration of a 'Buy' rating by EF Hutton, a reputable financial institution, is a positive signal for Atara Biotherapeutics. The maintained price target of $25 indicates that the analyst believes the stock has potential for growth. This could lead to increased investor confidence and potentially a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100